Skip to main content
Top
Published in: Malaria Journal 1/2020

Open Access 01-12-2020 | Chloroquin | Research

In silico and in vivo anti-malarial investigation on 1-(heteroaryl)-2-((5-nitroheteroaryl)methylene) hydrazine derivatives

Authors: Azar Tahghighi, Seyed-Mahdi Mohamadi-Zarch, Hamzeh Rahimi, Mahya Marashiyan, Naseh Maleki-Ravasan, Ali Eslamifar

Published in: Malaria Journal | Issue 1/2020

Login to get access

Abstract

Background

Resistance of Plasmodium falciparum against common anti-malarial drugs emphasizes the need of alternative and more effective drugs. Synthetic derivatives of 1-(heteroaryl)-2-((5-nitroheteroaryl)methylene) hydrazine have showed in vitro anti-plasmodial activities. The present study aimed to evaluate the molecular binding and anti-plasmodial activity of synthetic compounds in vivo.

Methods

The molecular docking was used to study the binding of compounds to haem and Plasmodium falciparum lactate dehydrogenase (PfLDH). Acute toxicity of the synthetic compounds was evaluated based on the modified up & down method. The anti-plasmodial activity of the compounds was conducted by the two standard tests of Peters’ and of Rane, using chloroquine-sensitive Plasmodium berghei in mice. Also, the toxicity to the internal organs of mice was evaluated on the seventh day after the treatment in addition to the histopathology of their liver. Compound 3 that showed high activity in the lowest dose was selected for further pharmacodynamic studies.

Results

According to the docking studies, the active site of PfLDH had at least four common residues, including Ala98, Ile54, Gly29, and Tyr97 to bind the compounds with the affinity, ranging from − 8.0 to − 8.4 kcal/mol. The binding mode of ligands to haem revealed an effective binding affinity, ranging from − 5.1 to − 5.5 kcal/mol. Compound 2 showed the highest  % suppression of parasitaemia (99.09%) at the dose of 125 mg/kg/day in Peters’ test. Compound 3, with 79.42% suppression, was the best in Rane’s test at the lowest dose (31 mg/kg/day). Compound 3 was confirmed by the pharmacodynamic study to have faster initial parasite elimination in the lowest concentration. The histopathology of the livers of mice did not reveal any focal necrosis of hepatocytes in the studied compounds.

Conclusions

The docking studies verified Pf LDH inhibition and the inhibitory effect on the haemozoin formation for the studied compounds. Accordingly, some compounds may provide new avenues for the development of anti-malarial drugs without liver toxicity, although further studies are required to optimize their anti-plasmodial activity.
Appendix
Available only for authorised users
Literature
3.
go back to reference Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med. 2017;23:917–28.CrossRef Blasco B, Leroy D, Fidock DA. Antimalarial drug resistance: linking Plasmodium falciparum parasite biology to the clinic. Nat Med. 2017;23:917–28.CrossRef
4.
go back to reference Ashley E, Dhorda M, Fairhurst R, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.CrossRef Ashley E, Dhorda M, Fairhurst R, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:411–23.CrossRef
5.
go back to reference WHO.World Malaria Report 2015. Geneva: World Health Organization; 2016. int/iris/bitstream/10665/200018/1/9789241565158_eng. pdf? ua = 1. Accessed Jan 2016. WHO.World Malaria Report 2015. Geneva: World Health Organization; 2016. int/iris/bitstream/10665/200018/1/9789241565158_eng. pdf? ua = 1. Accessed Jan 2016.
6.
go back to reference Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.CrossRef Nsanzabana C. Resistance to artemisinin combination therapies (ACTs): do not forget the partner drug! Trop Med Infect Dis. 2019;4:26.CrossRef
7.
go back to reference Bhattacharjee D, Shivaprakash G. Drug resistance in malaria—in a nutshell. J Appl Pharm Sci. 2016;6:137–43.CrossRef Bhattacharjee D, Shivaprakash G. Drug resistance in malaria—in a nutshell. J Appl Pharm Sci. 2016;6:137–43.CrossRef
8.
go back to reference Tahghighi A, Karimi S, Parhizgar AR, Zakeri S. Synthesis and anti-plasmodial activity of novel phenanthroline derivatives: an in vivo study. Iran J Basic Med Sci. 2018;21:202–11.PubMedPubMedCentral Tahghighi A, Karimi S, Parhizgar AR, Zakeri S. Synthesis and anti-plasmodial activity of novel phenanthroline derivatives: an in vivo study. Iran J Basic Med Sci. 2018;21:202–11.PubMedPubMedCentral
9.
go back to reference Christensen SB. Drugs and drug leads based on natural products for treatment and prophylaxis of malaria. In: Evidence-Based Validation of Herbal Medicine. PK Mukherjee, Ed. Elsevier; 2015:307-19. Christensen SB. Drugs and drug leads based on natural products for treatment and prophylaxis of malaria. In: Evidence-Based Validation of Herbal Medicine. PK Mukherjee, Ed. Elsevier; 2015:307-19.
10.
go back to reference Afrouzan H, Zakeri S, Mehrizi AA, Molasalehi S, Tahghighi A, Shokrgozar MA, et al. Anti-plasmodial assessment of four different Iranian propolis extracts. Arch Iran Med. 2017;20:270–81.PubMed Afrouzan H, Zakeri S, Mehrizi AA, Molasalehi S, Tahghighi A, Shokrgozar MA, et al. Anti-plasmodial assessment of four different Iranian propolis extracts. Arch Iran Med. 2017;20:270–81.PubMed
11.
go back to reference Hanboonkunupakarn B, White NJ. The threat of antimalarial drug resistance. Trop Dis Travel Med Vaccines. 2016;2:10.CrossRef Hanboonkunupakarn B, White NJ. The threat of antimalarial drug resistance. Trop Dis Travel Med Vaccines. 2016;2:10.CrossRef
12.
go back to reference Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015;70:2456–64.CrossRef Huttner A, Verhaegh EM, Harbarth S, Muller AE, Theuretzbacher U, Mouton JW. Nitrofurantoin revisited: a systematic review and meta-analysis of controlled trials. J Antimicrob Chemother. 2015;70:2456–64.CrossRef
13.
go back to reference Burri C, Chappuis F, Brun R. Human African trypanosomiasis. Manson’s Tropical Infectious Diseases (23rd Edn). 2014;606–21. Burri C, Chappuis F, Brun R. Human African trypanosomiasis. Manson’s Tropical Infectious Diseases (23rd Edn). 2014;606–21.
14.
go back to reference Jalkute CB, Barage H, Sonawane KD. Insight into molecular interactions of Aβ peptide and gelatinase from Enterococcus faecalis: a molecular modeling approach. RSC Adv. 2015;5:10488–96.CrossRef Jalkute CB, Barage H, Sonawane KD. Insight into molecular interactions of Aβ peptide and gelatinase from Enterococcus faecalis: a molecular modeling approach. RSC Adv. 2015;5:10488–96.CrossRef
15.
go back to reference D’Ursi P, Salvi E, Fossa P, Milanesi L, Rovida E. Modelling the interaction of steroid receptors with endocrine disrupting chemicals. BMC Bioinform. 2005;6:S10–7.CrossRef D’Ursi P, Salvi E, Fossa P, Milanesi L, Rovida E. Modelling the interaction of steroid receptors with endocrine disrupting chemicals. BMC Bioinform. 2005;6:S10–7.CrossRef
16.
go back to reference Penna-Coutinho J, Cortopassi WA, Oliveira AA, França TCC, Krettli AU. Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies. PLoS ONE. 2011;6:e21237.CrossRef Penna-Coutinho J, Cortopassi WA, Oliveira AA, França TCC, Krettli AU. Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies. PLoS ONE. 2011;6:e21237.CrossRef
17.
go back to reference HyperChem(TM) Professional 8.0, Hypercube, Inc., 1115 NW 4th Street, Gainesville, Florida 32601, USA. HyperChem(TM) Professional 8.0, Hypercube, Inc., 1115 NW 4th Street, Gainesville, Florida 32601, USA.
18.
go back to reference Koes DR, Baumgartner MP, Camacho CJ. Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J Chem Inf Model. 2013;53:1893–904.CrossRef Koes DR, Baumgartner MP, Camacho CJ. Lessons learned in empirical scoring with smina from the CSAR 2011 benchmarking exercise. J Chem Inf Model. 2013;53:1893–904.CrossRef
19.
go back to reference Laskowski RA, Swindells MB. LigPlot + : multiple ligand–protein interaction diagrams for drug discovery. Chem Inf Model. 2011;51:2778–86.CrossRef Laskowski RA, Swindells MB. LigPlot + : multiple ligand–protein interaction diagrams for drug discovery. Chem Inf Model. 2011;51:2778–86.CrossRef
20.
go back to reference Pant J, Deshpande SB. Acute toxicity of bisphenol A in rats. Indian J Exp Biol. 2012;50:425–9.PubMed Pant J, Deshpande SB. Acute toxicity of bisphenol A in rats. Indian J Exp Biol. 2012;50:425–9.PubMed
21.
go back to reference Peters W. The four-day suppressive in vivo antimalarial test. Ann Trop Med Parasitol. 1975;69:155–71.CrossRef Peters W. The four-day suppressive in vivo antimalarial test. Ann Trop Med Parasitol. 1975;69:155–71.CrossRef
22.
go back to reference National Research Council. Guide for the care and use of laboratory animals. Washington DC: National Academies Press; 1996. National Research Council. Guide for the care and use of laboratory animals. Washington DC: National Academies Press; 1996.
23.
go back to reference Ryley J, Peters W. The antimalarial activity of some quinolone esters. Ann Trop Med Parasitol. 1970;64:209–22.CrossRef Ryley J, Peters W. The antimalarial activity of some quinolone esters. Ann Trop Med Parasitol. 1970;64:209–22.CrossRef
24.
go back to reference Carleton HM, Drury RAB, Wallington EA. Carleton’s histological technique. Oxford: Oxford University Press; 1980. Carleton HM, Drury RAB, Wallington EA. Carleton’s histological technique. Oxford: Oxford University Press; 1980.
25.
go back to reference Suzuki S, Nakamura S, Koizumi T, Sakaguchi S, Baba S, Muro H, et al. The beneficial effect of a prostaglandin I2 analog on ischemic rat liver. Transplant. 1991;52:979–83.CrossRef Suzuki S, Nakamura S, Koizumi T, Sakaguchi S, Baba S, Muro H, et al. The beneficial effect of a prostaglandin I2 analog on ischemic rat liver. Transplant. 1991;52:979–83.CrossRef
26.
go back to reference Yang M, Ge JF, Arai C, Itoh I, Fu Q, Ihara M. Pharmacodynamics and pharmacokinetics studies of phenoxazinium derivatives for antimalarial agent. Bioorg Med Chem. 2009;15(17):1481–5.CrossRef Yang M, Ge JF, Arai C, Itoh I, Fu Q, Ihara M. Pharmacodynamics and pharmacokinetics studies of phenoxazinium derivatives for antimalarial agent. Bioorg Med Chem. 2009;15(17):1481–5.CrossRef
Metadata
Title
In silico and in vivo anti-malarial investigation on 1-(heteroaryl)-2-((5-nitroheteroaryl)methylene) hydrazine derivatives
Authors
Azar Tahghighi
Seyed-Mahdi Mohamadi-Zarch
Hamzeh Rahimi
Mahya Marashiyan
Naseh Maleki-Ravasan
Ali Eslamifar
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Malaria Journal / Issue 1/2020
Electronic ISSN: 1475-2875
DOI
https://doi.org/10.1186/s12936-020-03269-7

Other articles of this Issue 1/2020

Malaria Journal 1/2020 Go to the issue